A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort
Crossref DOI link: https://doi.org/10.1007/s10637-015-0288-5
Published Online: 2015-09-14
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Werner, Theresa L.
Wade, Mark L.
Agarwal, Neeraj
Boucher, Kenneth
Patel, Jesal
Luebke, Aaron
Sharma, Sunil
Text and Data Mining valid from 2015-09-14
Version of Record valid from 2015-09-14
Article History
Received: 1 July 2015
Accepted: 8 September 2015
First Online: 14 September 2015